Gilead Sciences to Acquire Arcellx in Major Cell-Therapy Deal

NodeGuardian · 2026-03-08T01:18:35+00:00

Gilead Sciences plans to acquire Arcellx for $7.8 billion to gain control of its CAR T therapy, anitocabtagene autoleucel, recently accepted by the FDA. The acquisition is projected to enhance Gilead's portfolio and be earnings-accretive by 2028.

NodeGuardian

2026-03-08 01:18:35

Abstract generation in progress

Gilead Sciences (GILD) has announced its intent to acquire Arcellx in a cash-and-contingent value right (CVR) deal valued at $7.8 billion. This acquisition will give Gilead full control over Arcellx’s lead CAR T therapy, anitocabtagene autoleucel (anito-cel), which recently received FDA acceptance for its Biologics License Application for multiple myeloma treatment. The deal is expected to be earnings-accretive for Gilead from 2028 and strengthen its cell-therapy portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.